Kezar Life Sciences, Inc. (KZR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
4000 Shoreline Court
South San Francisco, CA 94080
United States of America (the)
Phone
650 822 5600
Sector
Healthcare
Industry
Biotechnology
Employees
55
First IPO Date
June 21, 2018
| Name | Title | Pay | Year Born |
| Christopher J. Kirk | Co-Founder, Chief Executive Officer & Director | 632,000 | 1972 |
| John Franklin Fowler | Co-Founder & Director | 40,000 | 1972 |
| Mark Schiller | Chief Operations Officer | 483,600 | 1980 |
| Marc L. Belsky | Chief Financial Officer & Secretary | 653,208 | 1955 |
| Jack Taunton | Co-Founder | 0 | N/A |
| Pichi Chiang | Senior Vice President & Controller | 0 | 1962 |
Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.